CytoGenix Receives the 2006 Frost & Sullivan Technology Innovation Award for synDNA™

Frost & Sullivan has chosen CytoGenix as the recipient of the 2006 Technology Innovation Award in biotechnology processing for the development of the synDNA™ large-scale DNA production technology.

To identify the award recipient, Frost and Sullivan's analyst team tracks innovation in key hi-tech markets. The selection process includes extensive primary and secondary research.

In addition to the research methodology, the recipient must excel based on measurement criteria such as significance of the innovation in the industry, potential of the innovation to become the industry standard, competitive advantage, impact on company bottom-line and breadth of intellectual property and peer-reviewed scientific publication.

Dr. Malcolm Skolnick, CytoGenix, Inc. CEO, states, "Frost and Sullivan is the premium firm in biosciences market research with over forty years of experience in hi-tech markets."

"CytoGenix' synDNA™ has been selected as the best-in-class innovation in recognition of its revolutionary potential for changing DNA manufacture."

"Our technology will make DNA medicines such as vaccines readily available and accessible worldwide."

"Our short term goal is to develop synDNA™ vaccines including Avian Flu, small pox and Brucellosis as well as contract manufacturing of synDNA™ for other biotechnology companies."